IMMUNOGENIC COMPOSITIONS Russian patent published in 2023 - IPC A61K39/104 A61K39/108 A61K47/64 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of medicine, namely to an immunogenic composition containing (i) a framework polymer comprising a polymer and one or more antigenic polysaccharides conjugated with a polymer; and (ii) one or more polypeptide antigens in a non-covalent complex with a polymer and/or antigenic polysaccharide; in which the polymer is a capsule polysaccharide Klebsiella spp. K19; and in which each of one or more antigenic polysaccharides is an O-antigenic polysaccharide (OPS) of K. pneumoniae and/or P. aeruginosa; and in which each of one or more polypeptide antigens is independently selected from: flagellin P. aeruginosa, PcrV P. aeruginosa, MrkA K. pneumoniae, their antigenic fragments and their combinations; and moreover, the immunogenic composition is characterized by the fact that after administration to the subject it causes an immune response against Klebsiella and/or Pseudomonas, also refers to the immunogenic composition containing (a) a framework polymer comprising (i) a polymer containing the capsule polysaccharide Klebsiella spp. K19; and (ii) one or more antigenic polysaccharides containing the O-antigenic polysaccharide (OPS) Klebsiella and/or Pseudomonas conjugated with the capsule polysaccharide Klebsiella spp. K19; and (b) one or more polypeptide antigens in a non-covalent complex with a polymer due to at least one pair of affine molecules, including (i) the first affine molecule associated with the polymer; and (ii) a second affine molecule complementary to the first molecule and associated with one or more polypeptide antigens, where each of one or more polypeptide antigens is independently selected from: flagellin P. aeruginosa, PcrV P. aeruginosa, MrkA K. pneumoniae, their antigenic fragments or their combinations; and moreover, the immunogenic composition is characterized by the fact that after administration to the subject it causes an immune response against Klebsiella and/or Pseudomonas, also refers to vaccine compositions, also refers to a pharmaceutical composition containing one or more immunogenic compositions or vaccine compositions and a pharmaceutically acceptable carrier, where the pharmaceutical composition differs in that when administered to the patient it causes the immune response against Klebsiella and/or Pseudomonas also refers to the method for immunizing a patient against an infection caused by Klebsiella, and to the method for immunization of the patient against infection caused by P. aeruginosa.

EFFECT: group of inventions provides the development of technologies for the prevention and/or treatment of nosocomial infections and ensures the production of vaccines with sufficient immunogenicity to create immunity and prevent colonization.

71 cl, 98 dwg, 36 tbl, 16 ex